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Abstract
Background. Patients on maintenance haemodialysis treat-
ment experience an excessive risk of cardiovascular disease
and mortality. The vitamin A concentration is known to be
higher in these patients compared to the general population
where elevated vitamin A concentrations are associated
with adverse outcome. The impact of vitamin A on morbid-
ity and mortality in end-stage renal disease patients is
controversial and is the topic of this study.
Methods. We analysed plasma retinol and retinol-binding
protein 4 (RBP4) in 1177 diabetic haemodialysis patients,
who participated in the German Diabetes and Dialysis
Study (median follow-up 4 years). By Cox regression anal-
yses hazard ratios (HRs) were determined for pre-specified,
adjudicated end points according to baseline concentrations.
Results. Patients had a mean age of 66 6 8 years, mean
retinol and RBP4 concentrations of 3.28 (0.71–7.44) and
4.02 (1.28–10.1) lmol/L, respectively. Patients with retinol
concentrations in the first quartile (<2.6 lmol/L) had an
almost 2-fold increased risk of all-cause mortality com-
pared to patients of the fourth quartile [>3.9 lmol/L; HR
1.81, 95% confidence interval (CI) 1.43–2.30]. There was
a strong association between low retinol and the risk of
sudden cardiac death (SCD, HR 2.22, 95% CI 1.41–3.50)
and fatal infection (HR 2.19, 95% CI 1.26–3.82). Patients
with RBP4 concentrations in the lowest quartile (<3.0
lmol/L) were more likely to die of any cause (HR 1.43,
95% CI 1.14–1.80), experience SCD (HR 1.97, 95%
CI 1.28–3.03) and cardiovascular events (HR 1.43, 95%
CI 1.10–1.85).
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Conclusion. This large cohort study shows a strong asso-
ciation of low retinol and RBP4 concentrations with SCD
and all-cause mortality in diabetic haemodialysis patients.
Keywords: haemodialysis; mortality; retinol; retinol-binding protein 4;
sudden death
Introduction
Despite recent advances in renal replacement therapy,
mortality of dialysis patients remains high. The ERA-
EDTA reported a first-year mortality rate of 18% among
European dialysis patients [1]. Particularly in diabetic
patients, mortality is excessive with a 5-year survival rate
of only 35% [2]. The development of atherosclerosis
and cardiovascular disease (CVD) is one major cause
for mortality. Sudden cardiac death (SCD) represents
the most frequent event in these patients. Under diabetic
conditions, the increased formation of reactive oxidative
species (ROS) that result in endothelial dysfunction and
chronic inflammation accelerates the progression of athe-
rosclerosis and has been suggested as a potential risk
factor for CVD [3].
Besides well-established factors such as chronic hyper-
glycaemia elevated free fatty acids and uraemic toxins, an
impaired vitamin A metabolism might also have an im-
pact on increased ROS formation, oxidative stress and
oxidative tissue damage in diabetic patients with end-
stage renal disease (ESRD) [4]. The concentrations of
plasma retinol are increased in patients with kidney fail-
ure, which is mainly caused by a dysregulation of the
plasma retinol homeostasis. Physiologically, retinol con-
centration is regulated by the hepatic synthesis of its spe-
cific carrier retinol-binding protein 4 (RBP4), a small
visceral protein (21-kDa), which is catabolized by the
kidney after delivering retinol to target tissues. Thus,
the impaired renal catabolism of the retinol–RBP4 com-
plex in consequence of kidney failure leads to an accu-
mulation and abnormal supply of retinol to peripheral
tissues in ESRD patients [5].
Surprisingly, one recent case–control study reported a
significant association between low vitamin A plasma con-
centrations and carotid atherosclerosis in a small cohort of
ESRD patients [6]. Furthermore, it could be shown that low
retinol concentrations are associated with increased mortal-
ity in renal transplant recipients [7]. On the other hand,
increased concentrations of plasma RBP4 were shown to
be associated with the presence of microalbuminuria,
chronic kidney disease and clinical atherosclerosis in type
2 diabetic patients [8-11].
Taken together, the current data on retinol and RBP4
metabolism in renal patients are inconclusive. Furthermore,
the effects on specific clinical outcomes are unknown. The
aim of this study, therefore, was to investigate components
of the retinol transport complex and its association with
specific adverse outcomes in haemodialysis patients. To
that end, data of a large well-characterized cohort of dia-
betic haemodialysis patients were analysed [12].
Materials and methods
Study design and participants
The 4D study design has previously been reported in detail [13]. Briefly,
the 4D study was a prospective randomized controlled trial including 1255
patients with type 2 diabetes mellitus (T2DM), age 18–80 years and on
haemodialysis for <2 years. Between March 1998 and October 2002,
patients were recruited in 178 dialysis centres in Germany. After 4 weeks,
patients were randomly assigned to double-blinded treatment with either
20 mg atorvastatin (n ¼ 619) or placebo (n¼ 636) once daily. Study visits
took place at baseline and regularly after randomization until the date of
death, censoring or end of the study in March 2004. At each follow-up
visit, a blood sample was taken and an electrocardiogram and clinical
information including adverse events was recorded. Plasma was prepared
by centrifuging blood and kept frozen at 80C.
Definition of end points
The primary end point of the 4D study was defined as a composite of death
from cardiac causes, stroke and myocardial infarction (MI), whichever
occurred first. Death from cardiac causes comprised fatal MI (death within
28 days after an MI), SCD, death due to congestive heart failure (CHF),
death due to coronary heart disease during or within 28 days after an
intervention, and all other deaths ascribed to coronary heart disease.
SCD was considered as: death verified by terminal rhythm disorders in
an electrocardiogram; death by witnesses observed within 1 h after onset
of cardiac symptoms; death confirmed by autopsy; unexpected death,
presumably or possibly of cardiac origin and in the absence of a potassium
level 7.5 mmol/L before start of the three most recent haemodialysis
sessions. Stroke was defined as a neurologic deficit lasting longer than 24
h. Computed tomographic or magnetic resonance imaging was available in
all but 16 cases. MI was diagnosed when at least two of three criteria were
fulfilled: typical symptoms; elevated levels of cardiac enzymes; diagnostic
changes in the electrocardiogram. 4D Study end points were centrally
adjudicated by three members of the end point committee blinded to study
treatment and according to predefined criteria [12].
For the present analysis, the primary end point of cardiovascular events
(CVE), SCD, stroke, MI, death due to infection and all-cause mortality
were chosen to be separate outcome measures and based on the primary
judgment of the end point committee during the 4D Study. The study was
approved by the medical ethical committee, and all patients gave their
written informed consent before inclusion.
Data collection
Information on age, gender and smoking status was obtained through
patient interviews. Co-morbidities including the presence of coronary ar-
tery disease (CAD) and CHF, as well as the duration of diabetes mellitus
and dialysis treatment were reported by the patients’ nephrologists. CAD
was defined by a history of MI, coronary artery bypass grafting surgery
and percutaneous coronary intervention, and as documented by angiogra-
phy. CHF was defined according to the classification system of the New
York Heart Association. Blood pressure was measured in a sitting posi-
tion. Body mass index (BMI) was calculated as weight (kilogram) divided
by height (metre squared).
Analytical determination of retinol and RBP4
Retinol was determined using a modified gradient reversed-phase HPLC-
system (Waters, Eschborn, Germany) after organic extraction as previ-
ously described [14]. The detection limit for retinol was 2.0 ng, the
coefficient of variation (CV) between runs was 4%, and the recovery rate
was >95%. Concentrations of RBP4 in plasma were quantified using en-
zyme-linked immunosorbent assay as previously described [10]. The intra-
assay CV was 2.9% and the inter-assay CV was 4.2%.
Statistical analysis
Patient characteristics are presented according to quartiles of retinol and
RBP4 concentrations. Continuous variables were expressed as mean with
standard deviation or median with interquartile range as appropriate, and
categorical variables were expressed as percentages. First, we performed
correlation analyses for retinol and RBP4 with selected parameters repre-
sentative of nutrition and inflammation. The effects of retinol and RBP4 on
clinical outcomes were assessed by Kaplan–Meier estimates for incidences
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of the pre-specified end points. Furthermore, relative risks were derived
from Cox regression analyses, i.e. hazard ratios (HRs) and corresponding
95% confidence intervals (CI). The Cox regression analyses were adjusted
for the following confounders: age, gender, atorvastatin treatment, time on
dialysis, smoking status, systolic blood pressure, CAD and levels of phos-
phate and glycohaemoglobin A1c. Second, we performed additional Cox
regression analyses with inclusion of parameters reflecting lipid metabo-
lism, heart disturbances and anaemia, nutrition and inflammation, which
may represent intermediate conditions lying in the causal pathway of the
effect of retinol on adverse clinical events. The variables were included
stepwise in order to see the magnitude, by which the effect estimate for the
risk of retinol on adverse events changed, respectively. The analyses to
investigate the effect of RBP4 on adverse outcomes were performed in the
same way. All P-values are reported two-sided. Analyses were performed
using SPSS version 16.0.
Results
Patient characteristics
Between March 1998 and October 2002, a total of 1255
patients were included into the 4D study. The mean fol-
low-up period was 3.96 years (median 4.0 years) on atorvas-
tatin and 3.91 years (median 4.08 years) on placebo. Retinol
and RBP4 were measured in 1177 patients, in whom plasma
was available at baseline. Of those, 579 patients died during
follow-up, of whom 154 patients died of SCD and 118 due to
infection. A total of 447 patients reached the CVE with MI
and stroke occurring in 193 and 94 patients, respectively.
The median baseline concentrations of retinol were 3.18
lmol/L (range: 0.71-7.44 lmol/L) and of RBP4 3.84 lmol/L
(range: 1.28–10.1 lmol/L). The baseline characteristics of all
patients are shown in Table 1. Patients with higher retinol and
RBP4 concentrations (fourth quartile) were predominantly
male (67%), had a history of previous or current smoking,
shorter duration of diabetes and lower percentage of CHF and
arrhythmia compared to patients of the first quartile. With
decreasing retinol and RBP4, parameters of nutritional status
including total cholesterol, low-density lipoprotein (LDL) and
high-density lipoprotein (HDL) cholesterol were lower. Sim-
ilarly, albumin and phosphate levels were lower with decreas-
ing retinol and RBP4, while C-reactive protein (CRP) was
elevated (Table 1).
Relation of retinol and RBP4 to BMI, albumin and CRP
In correlation analyses, retinol and RBP4 were highly
related to each other (Pearson’s correlation coefficient
r ¼ 0.59, P < 0.001). Retinol showed a strong correlation
to albumin (r ¼ 0.38, P < 0.001) and to CRP (r ¼ 0.25,
P < 0.001), but not to BMI (r ¼ 0.02, P ¼ 0.483). Sim-
ilarly, RBP4 was strongly correlated to albumin (r ¼ 0.30,
P < 0.001), but considerably less to CRP (r ¼ 0.12,
P < 0.001). Again, no link between RBP4 and BMI was
detected (r ¼ 0.007, P ¼ 0.802).
Furthermore, we investigated the levels of retinol and
RBP4 in subgroups of patients with different CRP, albumin
and BMI status. In patients with high CRP (highest CRP
quartile >12.4 mg/L), mean retinol levels were lowest with
2.9 lmol/L as were the RBP4 levels with 3.8 lmol/L,
Table 1. Patient characteristics according to quartiles of baseline retinol and RBP4; study population n ¼ 1177a,b
Characteristic
Retinol (lmol/L) RBP4 (lmol/L)
 2.6,
(n ¼ 295)
>2.6  3.2,
(n ¼ 295)
>3.2  3.9,
(n ¼ 293)
>3.9,
(n ¼ 294)
 3.0,
(n ¼ 296)
>3.0  3.8,
(n ¼ 293)
>3.8  4.9,
(n ¼ 294)
>4.9,
(n ¼ 294)
Age, years 68 (7) 66 (8) 65 (8) 63 (8) 68 (8) 65 (8) 65 (8) 64 (9)
Gender, % male 39 48 61 67 44 52 59 60
BMI, kg/m2 27.3 (5.0) 27.9 (5.0) 27.7 (4.6) 27.6 (4.7) 27.2 (4.9) 28.2 (5.0) 27.4 (4.6) 27.7 (4.8)
Atorvastatin
treatment, %
51 48 49 49 50 52 52 49
Smoker/ex-smoker, % 33 40 44 44 36 42 39 45
Systolic BP, mmHg 143 (22) 148 (22) 149 (23) 145 (21) 145 (22) 146 (22) 147 (22) 146 (22)
Diastolic BP, mmHg 75 (11) 76 (11) 77 (12) 75 (11) 75 (10) 76 (11) 77 (12) 76 (11)
HbA1c, % 6.8 (1.3) 6.9 (1.2) 6.7 (1.2) 6.5 (1.2) 6.9 (1.3) 6.8 (1.3) 6.6 (1.2) 6.6 (1.2)
Duration of diabetes,
years
19.4 (9.0) 19.0 (8.1) 17.6 (8.9) 16.7 (8.9) 19.2 (8.7) 19.2 (8.0) 17.9 (9.0) 16.3 (9.0)
Time on dialysis
months
7 (6) 8 (7) 9 (7) 9 (8) 7 (7) 8 (7) 9 (7) 10 (7)
History of
CAD, % 30 29 27 32 34 26 25 33
CHF, % 44 36 37 29 40 38 35 32
Arrhythmia, % 21 22 15 16 26 16 16 16
Lipid values, mg/dL
Total cholesterol 208 (42) 218 (43) 223 (40) 228 (43) 206 (41) 219 (41) 221 (40) 232 (44)
LDL cholesterol 122 (30) 126 (31) 127 (30) 127 (29) 120 (29) 127 (29) 127 (30) 129 (31)
HDL cholesterol 37 (13) 36 (13) 36 (13) 36 (14) 37 (12) 36 (13) 37 (14) 36 (14)
Triglycerides 233 (145) 258 (167) 277 (178) 290 (72) 224 (136) 267 (171) 259 (157) 307 (189)
Phosphate, mg/L 5.5 (1.5) 6.0 (1.5) 6.2 (1.7) 6.4 (1.6) 5.5 (1.4) 5.9 (1.6) 6.2 (1.6) 6.5 (1.7)
CRP, mg/L 8.7 (3.8– 20.5) 5.4 (2.7–13.8) 4.2 (2.0– 9.4) 3.5 (1.5–7.7) 7.2 (3.4–20.6) 4.9 (2.6–11.7) 4.2 (1.7–9.6) 5.2 (2.0–11.1)
Albumin, g/dL 3.66 (0.30) 3.78 (0.30) 3.86 (0.28) 3.95 (0.27) 3.69 (0.31) 3.78 (0.29) 3.86 (0.27) 3.93 (0.29)
aValues are presented as means (SD) or median (interquartile range) or percentage.
bBP, blood pressure; HbA1c, glycated haemoglobin A1c; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
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respectively. Retinol and RBP4 were in contrast highest
with 3.6 and 4.3 lmol/L in patients of the first CRP quartile
(2.3 mL/L).
Similarly, retinol and RBP4 levels were lowest (2.8 and
3.4 lmol/L, respectively) in patients with low albumin
(first quartile 3.6 g/dL), while no meaningful difference
in retinol and RBP4 levels was found over the categories
of BMI. Combined analyses showed that patients with
both a high CRP (Quartile 4) and low albumin (Quartile
1) had even lower retinol levels of 2.5 lmol/L and RBP4
levels of 3.2 lmol/L, with similar results being obtained
from the subgroup of patients with all three conditions
(high CRP, low albumin and low BMI) being present:
retinol levels were 2.4 lmol/L and RBP4 3.0 lmol/L,
respectively.
Retinol status and total mortality
Retinol status at baseline was significantly associated with
all-cause mortality (see Figure 1). In unadjusted Cox
regression analyses, the risk of death decreased signifi-
cantly by 21% per unit increase (1 lmol/L) in retinol
(HR 0.79, 95% CI 0.72–0.87; Table 2). The association
was not meaningfully changed after adjustment for con-
founders, showing an 18% decrease in mortality per unit
increase in retinol (HR 0.82, 95% CI 0.75–0.91). We
especially evaluated further factors that potentially lie
in the causal pathway and may mediate the effect of ret-
inol on mortality (Table 2). With the stepwise inclusion
of CHF, arrhythmia, haemoglobin, total and LDL and
HDL cholesterol as well as BMI, the effect estimate did
not meaningfully change (Table 2). With additional inclu-
sion of CRP and albumin, however, and therewith ‘taking
out’ these potential pathways by the adjustments, the risk
of death was attenuated (Table 2), suggesting inflamma-
tion may play a major role in the mechanisms of retinol
to affect mortality.
In categorical analyses, the unadjusted hazard to die
was almost 2-fold higher in patients with low retinol
concentrations (first quartile) as compared to those with
high concentrations (fourth quartile) (HR 1.81, 95%
CI 1.43–2.30), (Table 3). This association remained
stable after controlling for confounders. Adjustments
for the intermediate variables as mentioned above
slightly reduced the effect estimate (HR 1.54, 95% CI
1.19–2.00), with additional adjustments for albumin and
CRP attenuating the association (HR 1.08, 95% CI
0.82–1.43).
Fig. 1. Kaplan–Meier curves for the time to all-cause mortality (a) SCD (b) and death due to infection (c) in subgroups of patients according
to baseline retinol plasma concentration (retinol Quartile 1: 2.6 lmol/L; Quartile 2: >2.6  3.2 lmol/L; Quartile 3: >3.2  3.9 lmol/L; Quartile
4: >3.9 lmol/L).
Table 2. HRs and 95% CI for all-cause mortality according to retinol and
RBP4 (continuous variables) at baseline
Retinol P RBP4 P
Crude model 0.79 (0.72–0.87) <0.001 0.91 (0.86–0.97) 0.004
Model 1a 0.82 (0.75–0.91) <0.001 0.93 (0.87–0.99) 0.030
Model 2b 0.85 (0.77–0.93) 0.001 0.95 (0.89–1.01) 0.083
Model 3c 0.85 (0.77–0.94) 0.002 0.96 (0.90–1.02) 0.184
Model 4d 0.98 (0.88–1.09) 0.687 1.01 (0.95–1.08) 0.693
aMain model: adjusted for confounders age, gender, atorvastatin treatment,
time on dialysis, glycated haemoglobin A1c, phosphate, smoking status,
CAD and systolic blood pressure.
bModel 1 plus additional adjustments for CHF, arrhythmia, haemoglobin.
cModel 2 plus additional adjustments for total, HDL and LDL cholesterol,
triglycerides and BMI.
dModel 3 plus additional adjustments for albumin and CRP.
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Retinol status and risk of SCD, stroke, MI and combined
CVE
Retinol concentration at baseline was strongly associated
with risk of SCD (Table 3 and Figure 1). Patients of the
lowest retinol quartile had a >2-fold increased risk of SCD
compared to those of the highest quartile (unadjusted HR
2.22, 95% CI 1.41–3.50). Even after adjustment for con-
founders patients in the first retinol quartile showed a 92%
greater hazard of SCD than patients of the fourth retinol
quartile. There were moderate trends of low retinol to affect
stroke and combined CVE, while no association with MI
was found (Table 3).
Retinol and risk of death due to infection
Patients with plasma retinol concentrations in the first quar-
tile had a 2.2-fold higher hazard for fatal infections than
patients in the fourth retinol quartile (crude HR 2.19, 95%
CI 1.26–3.82). The association became even stronger after
adjustment for confounders (adjusted HR 2.28, 95% CI
1.28–4.07).
RBP4 and total mortality
Results of RBP4 were similar to that of retinol. RBP4
plasma concentrations at baseline were significantly asso-
ciated with subsequent all-cause mortality (See Figure 2).
Per unit increase in RBP4 (1 lmol/L), the risk of death
decreased by 9% (HR 0.91, 95% CI 0.86–0.97; Table 2).
The results remained stable after adjustment for confound-
ers. Further adjustments for intermediate variables attenu-
ated the effect, with inflammation as reflected by CRP
and albumin hereby representing the major explanatory
pathway (HR 1.01, 95% CI 0.95–1.08).
The results of the categorical analyses are shown in Table 4.
Patients with RBP4 plasma concentrations of the first quar-
tile had a 43% increased risk of death compared to those
with high concentrations (fourth quartile) (HR 1.43, 95%
CI 1.14–1.80), Table 4). After adjustment for confounders,
this association was virtually unchanged.
RBP4 status and risk of SCD, stroke, MI, death due to
infection and combined CVE
Similarly to retinol, RBP4 concentrations were strongly asso-
ciated with the risk of SCD (Table 4 and Figure 2). Patients of
the lowest RBP4 quartile had an almost 2-fold higher risk of
SCD compared to those of the highest quartile (crude HR
1.97, 95% CI 1.28–3.03). Adjustment for confounders only
slightly decreased this association (HR 1.74, 95% CI 1.10–
2.74). There was a trend for an increased risk of stroke, while
MI and deaths due to infection were not affected. Considering
combined CVE, there was a 43% increased risk for patients
in the lowest RBP4 quartile, which remained virtually
unchanged after adjustments for confounders. Again, similar
to the observations for retinol, intermediate variables includ-
ing lipid status and particularly inflammation largely ex-
plained the effect of RBP4 on CVE by attenuating the
association (HR 1.15, 95% CI 0.86–1.53).
Discussion
In this study, we investigated the retinol metabolism in
1177 haemodialysis patients with T2DM, who took part in
the 4D Study and experienced a high incidence of pre-
specified and adjudicated end points. Our main findings
were that plasma concentrations of retinol and RBP4
were elevated as compared to the general population. In
outcome analyses, patients with higher retinol and RBP4
concentrations had a survival benefit. In this context, low
concentrations of retinol were associated with increased
Table 3. Risk HR and 95% CI of combined CVE, sudden death, death due to MI, death due to stroke, death due to infection and all-cause mortality by
quartiles of baseline retinol; study population n ¼ 1177
Outcome
HR (95% CI) according to baseline retinol
2.6, (n ¼ 295) >2.6  3.2, (n ¼ 295) >3.2  3.9, (n ¼ 293) >3.9, (n ¼ 294)
CVE
Crude 1.33 (1.03–1.72) 1.20 (0.93–1.54) 0.75 (0.57–0.99) 1
Adjusteda 1.27 (0.96–1.66) 1.13 (0.87–1.47) 0.74 (0.56–0.98) 1
SCD
Crude 2.22 (1.41–3.50) 1.50 (0.93–2.42) 1.27 (0.78–2.07) 1
Adjusteda 1.92 (1.18–3.11) 1.32 (0.81–2.15) 1.22 (0.74–2.00) 1
MI
Crude 1.01 (0.68–1.50) 1.02 (0.70–1.48) 0.74 (0.49–1.10) 1
Adjusteda 1.07 (0.70–1.62) 1.06 (0.72–1.56) 0.78 (0.52–1.17) 1
Stroke
Crude 1.51 (0.85–2.61) 1.51 (0.87–2.62) 0.62 (0.32–1.23) 1
Adjusteda 1.15 (0.62–2.12) 1.17 (0.66–2.06) 0.54 (0.27–1.07) 1
Death due to infection
Crude 2.19 (1.26–3.82) 1.61 (0.91–2.84) 1.97 (1.15–3.37) 1
Adjusteda 2.28 (1.28–4.07) 1.61 (0.90–2.87) 1.91 (1.11–3.29) 1
All-cause death
Crude 1.81 (1.43–2.30) 1.43 (1.12–1.81) 1.25 (0.98–1.60) 1
Adjusteda 1.67 (1.30–2.14) 1.32 (1.03–1.68) 1.19 (0.93–1.52) 1
aAnalyses were adjusted for age, gender, atorvastatin treatment, time on dialysis, glycated haemoglobin A1c, phosphate, smoking status, CAD and
systolic blood pressure.
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mortality, in particular, SCD and death due to infection.
Similarly, low concentrations of RBP4 were related to
higher risks of sudden and all-cause death and combined
CVE.
Our finding that plasma concentrations of retinol and
RBP4 were highly elevated in our patients as compared
to the general population, are in line with results from
previous studies addressing retinol status in patients with
chronic kidney disease [5, 6, 8–11]. The mechanism by
which physiological homeostatic regulated retinol is in-
creased in plasma of haemodialysis patients is unknown
so far. Apo-RBP4 (RBP4 unbound to retinol) is considered
as a positive feedback signal from the periphery indicating
the demand of target cells for retinol. Thus, an increased
utilization of retinol by tissues results in increased apo-
RBP4 levels stimulating the hepatic release of retinol. A
loss of kidney function leads to a decreased filtration and
degradation of RBP4 and a subsequent increase of apo-
Table 4. Risk HR and 95% CI of combined CVE, sudden death, death due to MI, death due to stroke, death due to infection and all-cause mortality by
quartiles of baseline RBP4; study population n ¼ 1177
Outcome
HR (95% CI) according to baseline RBP4
3.0, (n ¼ 296) >3.0  3.8, (n ¼ 293) >3.8  4.9, (n ¼ 294) >4.9, (n ¼ 294)
CVE
Crude 1.43 (1.10–1.85) 1.07 (0.82–1.40) 1.00 (0.77–1.30) 1
Adjusteda 1.41 (1.07–1.84) 1.12 (0.86–1.47) 1.01 (0.78–1.33) 1
SCD
Crude 1.97 (1.28–3.03) 1.15 (0.72–1.84) 0.94 (0.58–1.53) 1
Adjusteda 1.74 (1.10–2.74) 1.15 (0.71–1.86) 0.97 (0.60–1.58) 1
MI
Crude 1.14 (0.76–1.70) 1.11 (0.75–1.63) 0.88 (0.59–1.31) 1
Adjusteda 1.25 (0.83–1.90) 1.23 (0.83–1.83) 0.90 (0.60–1.35) 1
Death due to stroke
Crude 1.70 (0.96–3.03) 1.04 (0.56–1.93) 1.20 (0.66–2.17) 1
Adjusteda 1.45 (0.79–2.65) 0.96 (0.51–1.82) 1.15 (0.63–2.08) 1
Death due to infection
Crude 1.04 (0.61–1.77) 1.00 (0.60–1.68) 1.19 (0.73–1.92) 1
Adjusteda 0.98 (0.56–1.71) 0.97 (0.57–1.63) 1.15 (0.71–1.86) 1
All-cause death
Crude 1.43 (1.14–1.80) 1.09 (0.86–1.38) 1.06 (0.84–1.33) 1
Adjusteda 1.31 (1.03–1.67) 1.09 (0.86–1.39) 1.05 (0.83–1.33) 1
aAnalyses were adjusted for age, gender, atorvastatin treatment, time on dialysis, glycated haemoglobin A1c, phosphate, smoking status, CAD and
systolic blood pressure.
Fig. 2. Kaplan–Meier curves for the time to all-cause mortality (a) SCD (b) and CVE (c) in subgroups of patients according to baseline RBP4 plasma
concentration (RBP4 Quartile 1: 3.0 lmol/L; Quartile 2: >3.0  3.8 lmol/L; Quartile 3: >3.8  4.9 lmol/L; Quartile 4: >4.9 lmol/L).
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RBP4 serum concentration which possibly triggers an
enhanced retinol release from the liver [5, 15].
This study demonstrates a survival advantage in type
2 diabetic haemodialysis patients with high retinol con-
centrations compared to patients with lower retinol concen-
trations. It is important to note that low retinol plasma
concentrations in haemodialysis patients are still above
the recommended retinol plasma concentrations in healthy
individuals. The significant association between low plasma
retinol concentration and all-cause mortality persisted after
adjustment for potential confounders. Investigations in
other study cohorts of haemodialysis patients and renal
transplant recipients have shown similar results demon-
strating a higher risk for mortality, coronary heart disease
and/or CVE with lower retinol concentrations [6, 7, 16].
Our study adds important new information, addressing spe-
cific end points. In this context, our study identified SCD
and death due to infection as major targets of low retinol
concentrations. This observation of a reverse association of
vitamin A with adverse outcome is similar to that seen for
BMI or adiponectin in haemodialysis patients [17, 18].
Several studies demonstrated a better survival of over-
weight or obese haemodialysis patients compared to those
with normal weight or are underweight. In contrast to the
general population, being underweight is considered as a
major risk factor for mortality. Thus, highly elevated retinol
concentrations could possibly facilitate survival advantages
in haemodialysis patients. But what are the mechanisms
behind that?
Vitamin A is important for normal morphology and
function of epithelial cells in many organs of animals
and humans. It regulates monocytic differentiation and
function and influences the secretion of key cytokines by
macrophages [19]. Therefore in vitamin A deficiency, the
epithelial cells as first barrier to infection and the specific
immune response are affected. Vice versa, inflammation
results in a physiologic transient decline of vitamin A con-
centration during the acute phase response which returns
to pre-infection levels within a few days [19–21]. Patients
with ESRD are at a greater risk for inflammation due to
uraemia and the haemodialysis treatment per se [22]. In line
with these observations, a strong association between reti-
nol and CRP as well as albumin concentrations was seen
in this study. Interestingly, there was no association of
retinol with BMI. Regarding the increased mortality of
patients with low retinol levels, inflammation potentially
plays a major role, as the association of retinol with adverse
outcomes was attenuated after adjustment for albumin
and CRP. In this context, the literature is not unequivocal.
A study by Connolly et al. [7] (2007) demonstrated a
significant survival advantage at higher retinol concentra-
tions even after stratification for CRP in renal transplant
patients and explained this by anti-inflammatory or anti-
infective mechanisms. Apart from medication used in kid-
ney transplantation, differences in design, size and study
population need to be acknowledged, however, and may
contribute to explaining the different results when compar-
ing data from various studies.
With regard to molecular mechanisms, it is important to
mention that retinol is a precursor for the synthesis of reti-
noic acid isomers that influence the transcription of several
proteins by interacting with retinoic acid receptor and reti-
noid X receptor (RXR) nuclear receptors. One partner of
RXR is the peroxisome proliferator-activated receptor-alpha
(PPARa), which is expressed in heart and vascular cells.
PPARa plays a role in controlling the myocardial fatty acid
oxidation and prevents cardiac hypertrophy in animal studies
[23–25]. Of note, cardiac hypertrophy is a major risk factor
for SCD, the latter being strongly reduced at high concen-
trations of retinol in our study. In this context, the beneficial
effect of high retinol may have been mediated by PPARa.
Due to inhibition of inflammatory response by repressing
nuclear factor kappa B and interleukin-1 as well as reduction
of vascular cell adhesions molecule-1, PPARa maintain
normal endothelial function [25]. Therefore, the activation
of PPARa due to retinoid-activated RXR receptor can result
in cardio-protective effects.
The results of the present study furthermore showed that
lower RBP4 plasma concentrations were linked to a higher
mortality and a higher risk for CVE and SCD. Kalousova
et al. [16] demonstrated a positive effect of high RBP4
concentrations on overall and cardiovascular mortality in
haemodialysis patients. Furthermore, inverse correlations
of RBP4 with carotid artery echogenicity were observed in
the elderly supposing an involvement of RBP4 in the de-
velopment of atherosclerosis [26]. In contrast, high rather
than low RBP4 levels were associated with co-morbidities
including arteriosclerosis in patients with type 2 diabetes
[11]. Therefore, the role of RBP4 is not clear in diabetic
patients on haemodialysis. Our study provides new infor-
mation, identifying low RBP4 as an important risk factor
for adverse outcomes including combined CVE, mortality
and specifically SCD in this patient population.
In conclusion, this investigation shows, for the first time,
significant associations between low retinol plasma concen-
trations and a higher risks for all-cause mortality, SCD and
infectious deaths in a large well-characterized cohort of hae-
modialysis patients with T2DM. Furthermore, similar associ-
ations were seen for low RBP4, being a strong risk factor for
death, particularly SCD in these patients. Further investiga-
tions are needed to explore the underlying pathways in detail.
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